Oncolytics Biotech is an immuno-oncology company focused on advancing pelareorep, an intravenously delivered immuno-oncolytic virus, toward regulatory approval in metastatic breast cancer and other indications with high unmet needs. Oncolytics’ diverse clinical pipeline is supported by compelling clinical data demonstrating pelareorep’s safety, efficacy, immunotherapeutic mechanism of action, and potential to increase the proportion of patients responding to immune checkpoint inhibitors.
Ticker:
ONCY
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Alberta
Company HQ Country:
Canada
Year Founded:
Not Provided
Main Therapeutic Focus:
Oncology
Lead Product in Development:
pelareorep
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
